When was Biocrates founded?

Biocrates was founded in 2002 and raised its 1st funding round 4 years after it was founded.

Where is Biocrates located?

Biocrates is headquartered in Innsbruck, Austria.

Who is the current CEO of Biocrates?

Wulf Fischer-Knuppertz of Biocrates.

How many employees does Biocrates have?

As of Mar 31, 2026, the latest employee count at Biocrates is 50.

Is Biocrates a funded company?

Biocrates is a funded company, having raised a total of $7.9M across 9 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 23, 2006.

When was the latest funding round of Biocrates?

Biocrates' latest funding was a $***** Series B round on Sep 14, 2019, with participation from 2 investors. Its primary sector is Life Sciences Platforms and Tools. Globally, the Life Sciences Platforms and Tools sector has seen $921M in funding in 2026 to date.

Where does Biocrates rank among its competitors?

Biocrates ranks 42nd amongst 1961 active competitors, of which 453 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Life Biosciences, which secured $80M in Apr, 2026.

Who are the top competitors of Biocrates?

Biocrates' top competitors include Sutro Biopharma, Synthego and Avidity Biosciences. Among them, Life Biosciences secured the most recent funding round in April, 2026.

Biocrates - 2026 Company Profile, Team, Funding & Competitors

Company Details

Biocartes Life Sciences develops kits for targeted metabolic phenotyping solutions. The company has two product lines: Research and Diagnostic. The Research product line provides five sets of reagents and kits (AbsoluteIDQ) to analyze and quantify 188 metabolites from five different metabolite classes, including bile salts and steroids. The Diagnostic product line consists of the SteroIDQ Kit, a CE-marked in vitro diagnostic test for simultaneous quantitative analysis of 16 steroid hormones. It claims to use a proprietary software solution is to manage the entire analysis workflow, while enhancing the standardization and harmonization of project data processing.

Website: biocrates.com
Social

Key Metrics

Founded Year

2002

Location

Innsbruck, Austria

Stage

Acquired

Total Funding

$7.9M in 9 rounds

Latest Funding Round

Series B, Sep 14, 2019, $*****

Investors

MIG Fonds & 5 more

Ranked

42^nd among 1961 active competitors

Employee Count

50 as on Mar 31, 2026

Investment & Acquisitions

Metanomics Health

Similar Companies

Sutro Biopharma & 2674 more

Exit Details

Acquired by Bruker (Jun 03, 2025)

View Biocrates' full profile

Biocrates got acquired by Bruker on Jun 03, 2025.

Click here to take a look at Biocrates's acquisition in detail

Biocrates has raised a total funding of $7.9M over 9 rounds. Its first funding round was on Jun 23, 2006. Its latest funding round was a Series B round on Sep 14, 2019 for $*****. 2 investors participated in its latest round. Biocrates has 6 institutional investors.

Here is the list of recent funding rounds of Biocrates:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 14, 2019	4128174	Series B	4466614	7731054	5052564	4696708
Feb 01, 2018	2094464	Grant (prize money)	7715137	6026079	6810371	5320843
Jan 03, 2018	7484428	Series B	9316372	9871195	BASF & 2 more	5049563

Access funding benchmarks and valuations. Sign up today!

View details of Biocrates's funding rounds and investors

Biocrates' employee count trend

Biocrates has 50 employees as of Mar 26. Here is Biocrates's employee count trend over the years:

Uncover Biocrates' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biocrates include Sutro Biopharma, Synthego and Avidity Biosciences. Here is the list of Top 10 competitors of Biocrates, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
2nd	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
3rd	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	RTW Investments, Takeda Ventures & 19 others	70/100
4th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
5th	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
6th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
7th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Fidelity Investments, Invus & 14 others	64/100
8th	Life Biosciences 2017, Boston (United States), Series D	Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases	$261M	Alpha Wave Global, Globalive Capital & 12 others	64/100
9th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
10th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 12 others	63/100
42nd	Biocrates 2002, Innsbruck (Austria), Acquired	Developer of targeted metabolic phenotyping solutions	$7.9M	BASF, Arax Capital Partners & 4 others	56/100